AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
168.39
-1.52 (-0.89%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close169.91
Open168.68
Bid168.40 x 800
Ask171.51 x 900
Day's Range168.15 - 170.40
52 Week Range166.30 - 210.19
Volume2,144,250
Avg. Volume2,880,670
Market Cap102.707B
Beta (3Y Monthly)0.90
PE Ratio (TTM)13.43
EPS (TTM)12.54
Earnings DateJul 24, 2019 - Jul 29, 2019
Forward Dividend & Yield5.80 (3.23%)
Ex-Dividend Date2019-05-16
1y Target Est206.10
Trade prices are not sourced from all markets
  • Benzinga20 hours ago

    Medicines Company Rallies On Positive LDL Cholesterol Study Results

    Medicines Company announced interim results Saturday from the ongoing Phase 2 ORION-3 study that is evaluating the efficacy, safety and tolerability of inclisiran 300 mg in patients with atherosclerotic cardiovascular disease and elevated LDL cholesterol. The results show a consistent lowering of LDL cholesterol by more than 50 percent, with an overall follow-up of up to three years. The results were presented as a late-breaking presentation at the National Lipid Association Scientific Sessions in Miami.

  • Ligand Grants Preclinical Candidate Rights to UK-based Firm
    Zacks21 hours ago

    Ligand Grants Preclinical Candidate Rights to UK-based Firm

    Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.

  • Motley Fool4 days ago

    Who Had the Better Quarter: Gilead Sciences or Amgen?

    Here's which one of these large-cap biotechs put up the best numbers in the first quarter.

  • TheStreet.com4 days ago

    Bulls Make Money, Bears Make Money and Hogs Get Slaughtered, Jim Cramer Says

    That's Rule No. 5 of his '5 Rules for Trimming Your Winning Positions.'

  • Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting
    Investor's Business Daily5 days ago

    Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting

    Biotech companies Iovance Biotherapeutics, MacroGenics and Mirati Therapeutics were among the winners in a slew of data for cancer treatments released late Wednesday. Stocks rose Thursday.

  • PR Newswire5 days ago

    Amgen To Present At The RBC Healthcare Conference And The UBS Global Healthcare Conference

    THOUSAND OAKS, Calif., May 16, 2019 /PRNewswire/ -- Amgen (AMGN) will present at the RBC Health Care Conference at 8:30 a.m. ET and at the UBS Global Healthcare Conference at 2 p.m. ET on Tuesday, May 21, 2019, in New York City. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at both conferences. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.

  • Here's Why Mirati Therapeutics Is Surging Today
    Motley Fool5 days ago

    Here's Why Mirati Therapeutics Is Surging Today

    Lackluster results from Amgen's KRAS inhibitor program are clearing a path for Mirati's candidate.

  • Benzinga5 days ago

    What's Triggering The Rise In Mirati Shares?

    Mirati Therapeutics, Inc. (NASDAQ: MRTX ) shares were rallying by about 15 percent Thursday as traders circulated word that drugmaker Amgen, Inc. (NASDAQ: AMGN )  KRAS G12C  inhibitor abstract showed promising ...

  • Barrons.com5 days ago

    Big Biotech Needs Big M&A to Boost Their Beaten-Down Stocks

    The drug development pipelines of Gilead Sciences, Amgen and Biogen are running thin, and the companies might need to M&A to get going again, according to JPMorgan.

  • PR Newswire6 days ago

    Amgen Showcases Oncology Pipeline At ASCO 2019

    THOUSAND OAKS, Calif., May 15, 2019 /PRNewswire/ -- Amgen (AMGN) today announced that data from its oncology pipeline will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019. Seven investigational assets will be featured across a range of hematologic malignancies and solid tumors. "Biology and human genetics have been the foundation of Amgen's innovation for the last four decades," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.

  • GuruFocus.com6 days ago

    Insulet and West Pharma Proven Winners in Growing Wearable Devices Market

    With rapid growth projected for the market for wearable drug delivery devices, investors would be wise to consider some of the key players in the business. Two standouts are Boston-area-based Insulet (PODD) and West Pharmaceutical Services (WST), which is headquartered in Exton, Pennsylvania. Warning! GuruFocus has detected 4 Warning Signs with PODD.

  • 3 Stocks With Big News Coming at ASCO 2019
    Motley Fool6 days ago

    3 Stocks With Big News Coming at ASCO 2019

    These cancer drug developers could report market-moving news soon.

  • Benzinga6 days ago

    The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 14) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Avedro Inc ...

  • AbbVie Settles Humira Litigation With Boehringer Ingelheim
    Zacks6 days ago

    AbbVie Settles Humira Litigation With Boehringer Ingelheim

    AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.

  • Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer
    Zacks7 days ago

    Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer

    Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.

  • The Zacks Analyst Blog Highlights: Amgen, Altria, Booking, General Motors and Occidental
    Zacks7 days ago

    The Zacks Analyst Blog Highlights: Amgen, Altria, Booking, General Motors and Occidental

    The Zacks Analyst Blog Highlights: Amgen, Altria, Booking, General Motors and Occidental

  • Introducing Amgen (NASDAQ:AMGN), A Stock That Climbed 50% In The Last Five Years
    Simply Wall St.7 days ago

    Introducing Amgen (NASDAQ:AMGN), A Stock That Climbed 50% In The Last Five Years

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Top Stock Reports for Amgen, Altria & Booking Holdings
    Zacks8 days ago

    Top Stock Reports for Amgen, Altria & Booking Holdings

    Top Stock Reports for Amgen, Altria & Booking Holdings

  • Benzinga10 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

    Biotech stocks saw a reversal in sentiment as the week saw an earnings deluge from small-, micro- and nano-cap biotechs and some M&A activity . Here are some key catalysts for the unfolding week that should ...

  • PR Newswire11 days ago

    Amgen To Present At The Bank of America Merrill Lynch 2019 Health Care Conference

    THOUSAND OAKS, Calif. , May 10, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2019 Health Care Conference at 10 a.m. PT on Wednesday, May 15, 2019 . David W. ...

  • Reuters11 days ago

    Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

    Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients. Weekly U.S. prescription data from IQVIA, an analytics provider to the life sciences industry, showed that Lilly’s therapy Emgality claimed the largest share of first-time patients at 37.7 percent, for the first time outstripping Amgen’s Aimovig, whose share dropped to 37.2 percent as of April 26. Teva came in at a 25.1 percent share, according to an analyst who reviewed the data.

  • Radius (RDUS) Posts Narrower Q1 Loss, Misses on Revenues
    Zacks12 days ago

    Radius (RDUS) Posts Narrower Q1 Loss, Misses on Revenues

    Radius Health (RDUS) posts narrower-than-expected Q1 loss but Tymlos sales disappoint.

  • Biotech ETFs in Focus on String of Q1 Earnings Beats
    Zacks14 days ago

    Biotech ETFs in Focus on String of Q1 Earnings Beats

    Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.

  • Allergan (AGN) Beats on Q1 Earnings & Sales, Raises '19 View
    Zacks14 days ago

    Allergan (AGN) Beats on Q1 Earnings & Sales, Raises '19 View

    Allergan's (AGN) stock declines slightly in pre-market trading despite the company delivering earnings and revenue beat in the first quarter while marginally raising its guidance

  • Markit14 days ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    Amgen Inc NASDAQ/NGS:AMGNView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for AMGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding AMGN totaled $1.21 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. AMGN credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.